Access the full text.
Sign up today, get DeepDyve free for 14 days.
G. Tachedjian, J. Mellors, H. Bazmi, C. Birch, J. Mills (1996)
Zidovudine resistance is suppressed by mutations conferring resistance of human immunodeficiency virus type 1 to foscarnetJournal of Virology, 70
G. Tachedjian, M. Orlova, S. Sarafianos, Edward Arnold, S. Goff (2001)
Nonnucleoside reverse transcriptase inhibitors are chemical enhancers of dimerization of the HIV type 1 reverse transcriptaseProceedings of the National Academy of Sciences of the United States of America, 98
R. Pauwels, K. Andries, J. Desmyter, D. Schols, M. Kukla, H. Breslin, A. Raeymaeckers, J. Gelder, R. Woestenborghs, J. Heykants, K. Schellekens, M. Janssen, E. Clercq, P. Janssen (1990)
Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivativesNature, 343
N. Shulman, A. Zolopa, D. Passaro, R. Shafer, Wei Huang, D. Katzenstein, D. Israelski, N. Hellmann, C. Petropoulos, J. Whitcomb (2001)
Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapyAIDS, 15
Montaner JS
A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands
S. Moreno, J. Casado, M. Pérez-Elías, F. Dronda, A. Antela, A. Moreno, C. Gutiérrez (2003)
Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1.AIDS, 17 9
G. Tachedjian, H. Aronson, S. Goff (2000)
Analysis of mutations and suppressors affecting interactions between the subunits of the HIV type 1 reverse transcriptase.Proceedings of the National Academy of Sciences of the United States of America, 97 12
R. Haubrich, Carol A. Kemper, N. Hellmann, Philip Keiser, Mallory Witt, D. Forthal, J. Leedom, M. Leibowitz, J. Whitcomb, D. Richman, J. McCutchan (2002)
The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysisAIDS, 16
M. Baba, Hirofumi Tanaka, E. Clercq, R. Pauwels, J. Balzarini, D. Schols, H. Nakashima, C. Perno, R. Walker, T. Miyasaka (1989)
Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative.Biochemical and biophysical research communications, 165 3
D. Katzenstein, R. Bosch, N. Hellmann, Nan Wang, L. Bacheler, M. Albrecht (2003)
Phenotypic susceptibility and virological outcome in nucleoside-experienced patients receiving three or four antiretroviral drugsAIDS, 17
J. Jong, J. Goudsmit, V. Lukashov, M. Hillebrand, E. Baan, R. Huismans, S. Danner, J. Veen, F. Wolf, S. Jurriaans (1999)
Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs.AIDS, 13 1
Jimin Wang, LA Kohlstaedt, JM Friedman, MC Franklin, J. Wang, James Hartling, Akma Sattar, WH Konigsberg, M. Stahley, AB Kosek, T. Steitz, LF Silvian, SJ Smerdon (1992)
Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor.Science, 256 5065
D. Kuritzkes, Roland Bassett, V. Johnson, I. Marschner, J. Eron, J. Sommadossi, E. Acosta, R. Murphy, K. Fife, K. Wood, D. Bell, Ana Martínez, C. Pettinelli (2000)
Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: results of Adult AIDS Clinical Trials Group protocol 370AIDS, 14
C. Tantillo, Jianping Ding, A. Jacobo-Molina, R. Nanni, P. Boyer, S. Hughes, R. Pauwels, K. Andries, P. Janssen, Edward Arnold (1994)
Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance.Journal of molecular biology, 243 3
V. Merluzzi, K. Hargrave, M. Labadia, K. Grozinger, M. Skoog, Joe Wu, C. Shih, K. Eckner, S. Hattox, J. Adams (1990)
Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor.Science, 250 4986
T. Shirasaka, M. Kavlick, T. Ueno, W. Gao, E. Kojima, M. Alcaide, S. Chokekijchai, B. Roy, Edward Arnold, R. Yarchoan (1995)
Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides.Proceedings of the National Academy of Sciences of the United States of America, 92 6
S. Hammer, F. Vaida, K. Bennett, M. Holohan, L. Sheiner, J. Eron, L. Wheat, R. Mitsuyasu, R. Gulick, F. Valentine, J. Aberg, Michael Rogers, Cheryl Karol, A. Saah, Ronald Lewis, L. Bessen, C. Brosgart, V. DeGruttola, J. Mellors (2002)
Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.JAMA, 288 2
R. Leeuwen, C. Katlama, R. Murphy, K. Squires, J. Gatell, A. Horban, B. Clotet, S. Staszewski, A. Eeden, N. Clumeck, M. Moroni, A. Pavia, R. Schmidt, J. González-Lahoz, J. Montaner, F. Antunes, R. Gulick, D. Bánhegyi, M. Valk, P. Reiss, Liesbeth Weert, F. Leth, V. Johnson, J. Sommadossi, J. Lange (2003)
A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patientsAIDS, 17
De Clercq E
The role of non-nucleoside reverse transcriptase
Phillip FURMANt, A. James, FYFEf, M. CLAIRt, K. Weinhold, J. Rideout, G. Freeman, Sandra LEHRMANt, Samuel, Broder, H. Mitsuya, David BARRYt (1986)
Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase.Proceedings of the National Academy of Sciences of the United States of America, 83 21
C. Petropoulos, N. Parkin, K. Limoli, Y. Lie, T. Wrin, Wei Huang, H. Tian, Douglas Smith, G. Winslow, D. Capon, J. Whitcomb (2000)
A Novel Phenotypic Drug Susceptibility Assay for Human Immunodeficiency Virus Type 1Antimicrobial Agents and Chemotherapy, 44
G. Campiani, A. Ramunno, G. Maga, V. Nacci, C. Fattorusso, B. Catalanotti, E. Morelli, E. Novellino (2002)
Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: past, present, and future perspectives.Current pharmaceutical design, 8 8
J. Ding, K. Das, C. Tantillo, Wanyi Zhang, A. Clark, S. Jessen, Xiaode Lu, Y. Hsiou, A. Jacobo-Molina, K. Andries, R. Pauwels, H. Moereels, Luc Koymans, P. Janssen, Richard Smith, M.Kroeger Koepke, C. Michejda, S. Hughes, E. Arnold (1995)
Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor α-APA R 95845 at 2.8 å resolutionStructure, 3
V. Byrnes, E. Emini, W. Schleif, J. Condra, C. Schneider, W. Long, J. Wolfgang, D. Graham, L. Gotlib, A. Schlabach (1994)
Susceptibilities of human immunodeficiency virus type 1 enzyme and viral variants expressing multiple resistance-engendering amino acid substitutions to reserve transcriptase inhibitorsAntimicrobial Agents and Chemotherapy, 38
P. Harrigan, J. Montaner, Scott Wegner, W. Verbiest, V. Miller, R. Wood, B. Larder (2001)
World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testingAIDS, 15
Y. Hsiou, K. Das, Jianping Ding, A. Clark, J. Kleim, M. Rösner, I. Winkler, G. Riess, S. Hughes, Edward Arnold (1998)
Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: inhibitor flexibility is a useful design feature for reducing drug resistance.Journal of molecular biology, 284 2
N. Parkin, N. Hellmann, J. Whitcomb, Linda Kiss, C. Chappey, C. Petropoulos (2004)
Natural Variation of Drug Susceptibility in Wild-Type Human Immunodeficiency Virus Type 1Antimicrobial Agents and Chemotherapy, 48
Deeks SG
International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance.
M. Hirsch, F. Brun-vezinet, B. Clotet, B. Conway, D. Kuritzkes, R. D’Aquila, L. Demeter, S. Hammer, V. Johnson, C. Loveday, J. Mellors, D. Jacobsen, D. Richman (2003)
Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 37 1
N. Shulman, A. Zolopa, D. Passaro, U. Murlidharan, D. Israelski, C. Brosgart, Michael Miller, S. Doren, R. Shafer, D. Katzenstein (2000)
Rapid Communication: Efavirenz- and Adefovir Dipivoxil–Based Salvage Therapy in Highly Treatment-Experienced Patients: Clinical and Genotypic Predictors of Virologic ResponseJournal of Acquired Immune Deficiency Syndromes, 23
D. Pillay, S. Taylor, D. Richman (2000)
Incidence and impact of resistance against approved antiretroviral drugsReviews in Medical Virology, 10
E. Clercq (1998)
The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infectionAntiviral Research, 38
T. Dueweke, S. Poppe, D. Romero, Swaney Sm, A. So, K. Downey, I. Althaus, F. Reusser, M. Busso, L. Resnick (1993)
U-90152, a potent inhibitor of human immunodeficiency virus type 1 replicationAntimicrobial Agents and Chemotherapy, 37
M. Winters, Kristi Coolley, Yvette Girard, D. Levee, H. Hamdan, R. Shafer, D. Katzenstein, T. Merigan (1998)
A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors.The Journal of clinical investigation, 102 10
B. Larder (1992)
3'-Azido-3'-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitorsAntimicrobial Agents and Chemotherapy, 36
S. Young, S. Britcher, L. Tran, L. Payne, W. Lumma, T. Lyle, J. Huff, P. Anderson, D. Olsen, S. Carroll, D. Pettibone, J. O'brien, R. Ball, S. Balani, J. Lin, I. Chen, W. Schleif, V. Sardana, W. Long, V. Byrnes, E. Emini (1995)
L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptaseAntimicrobial Agents and Chemotherapy, 39
L. Bacheler, S. Jeffrey, G. Hanna, R. D’Aquila, L. Wallace, K. Logue, B. Cordova, K. Hertogs, B. Larder, R. Buckery, D. Baker, Karen Gallagher, H. Scarnati, R. Tritch, C. Rizzo (2001)
Genotypic Correlates of Phenotypic Resistance to Efavirenz in Virus Isolates from Patients Failing Nonnucleoside Reverse Transcriptase Inhibitor TherapyJournal of Virology, 75
Y. Hsiou, Jianping Ding, Jianping Ding, K. Das, A. Clark, P. Boyer, P. Lewi, P. Janssen, J. Kleim, M. Rosner, S. Hughes, Edward Arnold (2001)
The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance.Journal of molecular biology, 309 2
P. Clevenbergh, E. Cua, E. Dam, J. Durant, J. Schmit, R. Boulmé, J. Cottalorda, A. Beyou, J. Schapiro, F. Clavel, P. Dellamonica (2002)
Prevalence of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance-associated mutations and polymorphisms in NNRTI-naïve HIV-infected patientsHIV Clinical Trials, 3
A. Babiker, J. Darbyshire, D. Cooper, M. Hooker, R. Withnall, P. Yeni (2001)
An open-label randomized trial to evaluate different therapeutic strategies of combination therapy in HIV-1 infection: design, rationale, and methods of the initio trial.Controlled clinical trials, 22 2
N. Shulman, A. Zolopa, D. Passaro, Usha Murlidharan, D. Israelski, C. Brosgart, Michael Miller, Sally Doren, R. Shafer, D. Katzenstein (2000)
Rapid Communication: Efavirenz‐ and Adefovir Dipivoxil‐Based Salvage Therapy in Highly Treatment‐Experienced Patients: Clinical and Genotypic Predictors of Virologic ResponseJAIDS Journal of Acquired Immune Deficiency Syndromes, 23
Moyle G
The emerging roles of non-nucleoside reverse transcriptase inhibitors in antiretroviral therapy.
M. Harris, J. Montaner (2000)
Clinical uses of non‐nucleoside reverse transcriptase inhibitorsReviews in Medical Virology, 10
R. D’Aquila, J. Schapiro, F. Brun-vezinet, B. Clotet, B. Conway, L. Demeter, R. Grant, V. Johnson, D. Kuritzkes, C. Loveday, R. Shafer, D. Richman (2003)
Drug resistance mutations in HIV-1.Topics in HIV medicine : a publication of the International AIDS Society, USA, 11 3
R. Esnouf, Jingshan Ren, C. Ross, Y. Jones, D. Stammers, D. Stuart (1995)
Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitorsNature Structural Biology, 2
K. Laethem, M. Witvrouw, C. Pannecouque, B. Remoortel, J. Schmit, R. Esnouf, J. Kleim, J. Balzarini, J. Desmyter, E. Clercq, A. Vandamme (2001)
Mutations in the non-nucleoside binding-pocket interfere with the multi-nucleoside resistance phenotypeAIDS, 15
K. Rittinger, G. Divita, R. Goody (1995)
Human immunodeficiency virus reverse transcriptase substrate-induced conformational changes and the mechanism of inhibition by nonnucleoside inhibitors.Proceedings of the National Academy of Sciences of the United States of America, 92 17
D. Arion, N. Kaushik, Suzanne McCormick, Gadi Borkow, M. Parniak (1998)
Phenotypic mechanism of HIV-1 resistance to 3'-azido-3'-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase.Biochemistry, 37 45
Shulman NS
Efavirenz- and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: clinical and genotypic predictors of virologic response.
J. Whitcomb, N. Parkin, C. Chappey, N. Hellmann, C. Petropoulos (2003)
Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates.The Journal of infectious diseases, 188 7
Schlomo Staszewski, J. Morales-Ramirez, K. Tashima, A. Rachlis, D. Skiest, James Stanford, R. Stryker, P. Johnson, Dominic Labriola, Dianne Farina, D. Manion, N. Ruiz (1999)
Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team.The New England journal of medicine, 341 25
TW th, S. Demars, DL Palmer, M. Altman, J. Moore (1990)
Human immunodeficiency virus.Journal of the American Podiatric Medical Association, 80 9
H. Huang, R. Chopra, G. Verdine, S. Harrison (1998)
Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance.Science, 282 5394
Jingshan Ren, R. Esnouf, A. Hopkins, E. Jones, I. Kirby, James Keeling, C. Ross, B. Larder, David Stuart, D. Stammers (1998)
3'-Azido-3'-deoxythymidine drug resistance mutations in HIV-1 reverse transcriptase can induce long range conformational changes.Proceedings of the National Academy of Sciences of the United States of America, 95 16
M. Albrecht, R. Bosch, S. Hammer, S. Liou, H. Kessler, M. Para, J. Eron, H. Valdez, M. Dehlinger, D. Katzenstein (2001)
Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection.The New England journal of medicine, 345 6
P. Kellam, C. Boucher, B. Larder (1992)
Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine.Proceedings of the National Academy of Sciences of the United States of America, 89
S. Sarafianos, K. Das, A. Clark, Jianping Ding, P. Boyer, S. Hughes, Edward Arnold (1999)
Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids.Proceedings of the National Academy of Sciences of the United States of America, 96 18
G. Tachedjian, S. Goff (2003)
The effect of NNRTIs on HIV reverse transcriptase dimerization.Current opinion in investigational drugs, 4 8
B. Larder, S. Bloor, S. Kemp, K. Hertogs, R. DeSmet, V. Miller, Martin Stürmer, Schlomo Staszewski, Jingshan Ren, D. Stammers, David Stuart, R. Pauwels (1999)
A Family of Insertion Mutations between Codons 67 and 70 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confer Multinucleoside Analog ResistanceAntimicrobial Agents and Chemotherapy, 43
D. Rodgers, S. Gamblin, B. Harris, S. Ray, J. Culp, B. Hellmig, D. Woolf, C. Debouck, S. Harrison (1995)
The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1.Proceedings of the National Academy of Sciences of the United States of America, 92 4
S. Deeks (2001)
Nonnucleoside Reverse Transcriptase Inhibitor ResistanceJAIDS Journal of Acquired Immune Deficiency Syndromes, 26
D. Richman, D. Havlir, Jacques Corbeil, David Looney, C. Ignacio, Stephen Spector, John Sullivan, Sarah Cheeseman, Kevin Barringer, Dan Pauletti, Cheng-Kon Shih, Maureen Myers, Johanna Griffin (1994)
Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapyJournal of Virology, 68
J. Montaner, P. Reiss, D. Cooper, S. Vella, M. Harris, B. Conway, M. Wainberg, Richard Smith, P. Robinson, D. Hall, M. Myers, J. Lange (1998)
A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study.JAMA, 279 12
A. Jacobo-Molina, Jianping Ding, R. Nanni, A. Clark, Xiaode Lu, C. Tantillo, Roger Williams, G. Kamer, A. Ferris, P. Clark, A. Hizi, Stephen Hughesi, Edward Arnold (1993)
Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA.Proceedings of the National Academy of Sciences of the United States of America, 90 13
M. Stürmer, S. Staszewski, H. Doerr, B. Larder, S. Bloor, K. Hertogs (2003)
Correlation of Phenotypic Zidovudine Resistance with Mutational Patterns in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1: Interpretation of Established Mutations and Characterization of New Polymorphisms at Codons 208, 211, and 214Antimicrobial Agents and Chemotherapy, 47
B. Larder, S. Kemp (1989)
Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT).Science, 246 4934
Campiani G
Non-nucleoside HIV-1 reverse
Ralph Spence, WM Kati, K. Anderson, Kate Johnson (1995)
Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitorsScience, 267
Peter Meyer, S. Matsuura, A. Mian, A. So, W. Scott (1999)
A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase.Molecular cell, 4 1
D. Hooker, G. Tachedjian, A. Solomon, A. Gurusinghe, S. Land, C. Birch, J. Anderson, B. Roy, E. Arnold, N. Deacon (1996)
An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3'-azido-3'-deoxythymidineJournal of Virology, 70
C. Briones, V. Soriano, C. Dona, P. Barreiro, J. González-Lahoz (2000)
Can early failure with nevirapine be rescued with efavirenzJournal of Acquired Immune Deficiency Syndromes, 24
R. Shafer, R. Kantor, M. Gonzales (2000)
The Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors.AIDS reviews, 2 4
J. Whitcomb, Wei Huang, K. Limoli, E. Paxinos, T. Wrin, G. Skowron, S. Deeks, M. Bates, N. Hellmann, C. Petropoulos (2002)
Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlatesAIDS, 16
Nonnucleoside reverse transcriptase inhibitors (NNRTI) are used to treat HIV-infected individuals in combination with nucleoside analogues (NRTI) and protease inhibitors. Long-term treatment with antiretroviral agents results in the emergence of strains with decreased susceptibility (resistance) to the drugs and is one of the major factors in loss of drug efficacy. Conversely, there have been recent reports of HIV strains with increased susceptibility (hypersusceptibility) to NNRTIs. These isolates emerge in patients on long-term antiretroviral therapy particularly in individuals receiving NRTIs. The prevalence of NNRTI hypersusceptibility ranges between 17.5 and 50% in NRTI-treatment experienced compared to 10% in NRTI-naïve patients. There is an inverse correlation between NNRTI hypersusceptibility and phenotypic NRTI resistance and a direct correlation between the number of NRTI resistance mutations present in the HIV reverse transcriptase. Re-sensitisation of phenotypic NNRTI resistance has been reported by NRTI mutations and is not likely to be detected using genotypic resistance assays. Recent studies demonstrate that NNRTI hypersusceptible virus at baseline is likely to predict better virological outcomes in patients on NNRTI-based salvage regimens compared to patients with NNRTI susceptible virus. These studies have implications for the sequence of antiretroviral drug use where patients may benefit from NRTI therapy before the introduction of NNRTIs, however more studies are needed to examine this treatment rationale.
Sexual Health – CSIRO Publishing
Published: Jun 24, 2004
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.